Clinical Trial Update: Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10 [Phase 2]

View source ↗

Summary

Phase 2 study assessing the immunogenicity, tolerability, and safety of one or two doses of an adjuvanted swine-origin H1N1 influenza vaccine in adults 18+ who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• H1N1 influenza vaccine, adjuvanted (influenza vaccine, H1N1, adjuvanted)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic Influenza Disease | Phase 2 | Status: COMPLETED